Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.95 |
| ▸ | MEN1 | O00255 | 4/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.95 |
| ▸ | HPGD | P15428 | 4/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.95 |
| ▸ | USP2 | O75604 | 2/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.95 |
| ▸ | CASP1 | P29466 | 2/20 | 0.95 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.95 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.95 |
| ▸ | HTT | P42858 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.95 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.95 |
| ▸ | IDO1 | P14902 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichlorophen SCHEMBL9109126 | 0.98 | CYP3A4 (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL29524636 | 0.98 | CYP3A4 (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL18052 | 0.98 | CYP3A4 (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL29349447 | 0.98 | CYP3A4 (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL735904 | 0.95 | CYP3A4 (0.95) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL16619827 | 0.93 | CYP3A4 (0.91) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| SCHEMBL15459929 | 0.89 | HIF1A (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| SCHEMBL15459933 | 0.89 | HIF1A (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| Dichlorophen SCHEMBL5614299 | 0.89 | CYP3A4 (0.83) | CYP3A4HIF1AMEN1KMT2AHPGD | |
| SCHEMBL6115713 | 0.89 | HIF1A (1.00) | CYP3A4HIF1AMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2018191719-A1 | LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Acuitas Therapeutics, Inc. (CA) | 2018-10-18 | — | — | WO | disclosed |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | ASTRAZENECA AB (SE) | 2013-06-27 | — | — | US | disclosed |
| US-8343996-B2 | Azaquinolinone derivatives and uses thereof | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| CN-102369202-A | Azaquinolinone derivatives and uses thereof | LINK MEDICINE CORP | 2012-03-07 | — | — | CN | disclosed |
| EP-2370436-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | Link Medicine Corporation (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010057006-A9 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010057006-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1753782-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1299395-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002004462-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| CN-1313855-A | Inhibitors of alpha4Betal mediated cell adhesion alpha Beta | UPJOHN CO (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | TPMT, AZI2, NNMT | CYP3A4 1261/4885HIF1A 2381/4885MEN1 801/4885 |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | CYP3A4 3553/4885HIF1A 494/4885MEN1 4300/4885 |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | TPMT, AZI2, NNMT | CYP3A4 1261/4885HIF1A 2381/4885MEN1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.